Table 2.

Clinical features of C-Circle positive tumors in the INFORM cohort (n = 40)^a.

	Total cohort		C-Circle positive		C-Circle negative		P valueg
	No.f	%f	No.f	%f	No.f	%f
Total	40		19	47.5%	21	52.5%
Stage 1-3b	4	10.0%	4	21.1%	0	0.0%	0.041
Stage 4b	34	85.0%	14	73.7%	20	95.2%
Stage 4Sb	2	5.0%	1	5.3%	1	4.8%	1.000
LR/IRc	7	17.5%	5	26.3%	2	9.5%	0.226
HRc	33	82.5%	14	73.7%	19	90.5%
Male	32	80.0%	13	68.4%	19	90.5%	0.120
Female	8	20.0%	6	31.6%	2	9.5%
Aged (mean in days)	1645		2243		1104		0.003
MYCN ampe	11	27.5%	2	10.5%	9	42.9%	0.029
MYCN normale	28	70.0%	17	89.5%	10	47.6%

^an refers to the number of tumors.

^bTumor staging was done according to the INSS criteria.

^cRisk stratification was based on the German Neuroblastoma Study NB2004.

^dAge at diagnosis.

^eMYCN status refers to MYCN status at diagnosis, which is either amplified (amp, ≥8 copies) or normal. MYCN status was inconclusive for one tumor at diagnosis.

^fAll values are given in absolute number of tumors (No.) and relative (%) to the total number of tumors in each group (total cohort, C-Circle positive, C-Circle negative).

^gP values were calculated using Fisher tests and two-sided Wilcoxon rank sum test (age).